No Data
No Data
Purple Biotech Unveils CAPTN-3 Cancer Therapy
Purple Biotech Regains Nasdaq Compliance
HC Wainwright & Co. Maintains Buy on Purple Biotech, Adjusts Price Target To $33 (1-20 Reverse Stock Split)
H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33
H.C. Wainwright analyst Emily Bodnar maintains $Purple Biotech(PPBT.US)$ with a buy rating, and adjusts the target price from $200 to $33.According to TipRanks data, the analyst has a success rate
Purple Biotech Says Pancreatic Cancer Study Data Shows CM24 With Nivolumab and Chemo Improves Survival
Purple Biotech Reveals Optimistic Cancer Treatment Data